Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: Results of a 12-week, phase II, dose-finding study
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Identificadores![](/xmlui/themes/Mirage2//images/despl_identif.png)
Identificadores
Fecha de publicación
2011Título de revista
BMC MUSCULOSKELETAL DISORDERS
Tipo de contenido
Artigo
![](/xmlui/themes/Mirage2//images/final_lines.png)